BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 1, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Cereno completes preclinical safety program for antithrombotic candidate
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Hematologic
Cereno completes preclinical safety program for antithrombotic candidate
Dec. 4, 2023
No Comments
Cereno Scientific AB has completed the preclinical safety program for CS-014, a histone deacetylase (HDAC) inhibitor in development for arterial and venous thrombosis prevention.
BioWorld Science
Hematologic